Previous 10 | Next 10 |
Centogene N.V. (CNTG) has expanded its partnership with PTC Therapeutics (PTCT). The companies will work together to provide genetic testing and 3-O-Methyldopa (3-OMD) biomarker analytics to help identify patients with Aromatic L-amino Acid Decarboxylase ((AADC)) deficiency, a rare genet...
PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference PR Newswire SOUTH PLAINFIELD, N.J., Nov. 19, 2020 SOUTH PLAINFIELD, N.J. , Nov. 19, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that manag...
The FDA has designated both Orphan Drug Designation and Fast Track status to PTC Therapeutics' (PTCT) PTC596 for the treatment of leiomyosarcoma ((LMS)), a rare type of cancer that affects smooth muscle tissue.Furthermore, the FDA has also granted PTC596 a Rare Pediatric Disea...
PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications PR Newswire SOUTH PLAINFIELD, N.J., Nov. 18, 2020 SOUTH PLAINFIELD, N.J. , Nov. 18, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDA...
PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program - Initial clinical trial results expected in 1H 2021 - PR Newswire SOUTH PLAINFIELD, N.J., Nov. 17, 2020 SOUTH PLAINFIELD, N.J. , Nov. ...
PTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare Diseases - AADC deficiency associated with high and accumulating disease burden, demonstrating the need for access to an effective therapy - - Patient and caregiver quality of life...
PTC Therapeutics, Inc. (PTCT) Q3 2020 Earnings Conference Call October 29, 2020 16:30 Company Participants Lisa Hayes - Vice President Investor Relations Stuart Peltz - Chief Executive Officer Emily Hill - Chief Financial Officer Matt Klein - Chief Development Officer Eric Pauwels - Chief Bus...
PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update - Evrysdi™ makes rapid progress with multiple international approvals and strong U.S. launch - - Total net revenue of $118.4 million, 66% YoY increase; Total net product reve...
PTC Therapeutics (NASDAQ:PTCT) is scheduled to announce Q3 earnings results on Thursday, October 29th, after market close.The consensus EPS Estimate is $1.84 (+273.6% Y/Y) and the consensus Revenue Estimate is $112.21M (+57.1% Y/Y).Over the last 2 years, PTCT has beaten EPS estimates 25% of t...
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences PR Newswire SOUTH PLAINFIELD, N.J., Oct. 28, 2020 SOUTH PLAINFIELD, N.J. , Oct. 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will p...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....